SEHK:1548Life Sciences
A Look At Genscript Biotech (SEHK:1548) Valuation After CARVYKTI Q4 2025 Sales Momentum
Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction.
See our latest analysis for Genscript Biotech.
Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...